SCHEMBL3953808

SCHEMBL3953808

CCCc1nnc(C(Cc2ccc(-c3cccc(CNC)c3)cc2)OCC)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 6/20 0.41
EPHX2 P34913 1/20 0.37
MAPT P10636 1/20 0.34
HTR7 P34969 1/20 0.34
MME P08473 1/20 0.34
NMT1 P30419 1/20 0.34
ATR Q13535 1/20 0.33
ADAMTS4 O75173 2/20 0.32
ADAMTS5 Q9UNA0 2/20 0.32
NOS3 P29474 2/20 0.32
NOS1 P29475 2/20 0.32
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
FFAR1 O14842 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953810 0.87 MAOB (0.38) MAPTHTR7MMEMEN1KMT2A
SCHEMBL3943634 0.78 MEN1 (0.42) MAPTMEN1HTTKMT2AL3MBTL1
SCHEMBL3945263 0.75 HSD17B2 (0.45) MAPTADAMTS4ADAMTS5MEN1HTT
SCHEMBL6277888 0.75 RAB9A (0.38) MAPTMEN1HTTKMT2AL3MBTL1
SCHEMBL6251654 0.72 AOC3 (0.39) MAPTMEN1HTTKMT2AL3MBTL1
SCHEMBL3943679 0.72 HSD17B2 (0.40) ADAMTS4ADAMTS5MEN1KMT2AL3MBTL1
SCHEMBL5399548 0.69 PPARG (0.55)
SCHEMBL5399556 0.69 PPARG (0.55)
SCHEMBL3950853 0.68 PRMT6 (0.45) PRMT6EPHX2HTR7MMEFFAR1
SCHEMBL1252083 0.63 PRMT6 (0.73) PRMT6EPHX2MAPTHTR7NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582663-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-09-01 US disclosed
US-20080070957-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2008-03-20 US disclosed
US-7285568-B2 Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-10-23 US disclosed
US-20060004048-A1 Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070957-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD PRMT6 4272/4885EPHX2 1198/4885MAPT 3651/4885
US-20060004048-A1 Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD PRMT6 4261/4885EPHX2 1707/4885MAPT 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.